Original language | English |
---|---|
Article number | e70052 |
Number of pages | 5 |
Journal | HemaSphere |
Volume | 8 |
Issue number | 11 |
DOIs | |
Publication status | Published - 1 Nov 2024 |
Access to Document
- 10.1002/hem3.70052Licence: CC BY-NC-ND
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: HemaSphere, Vol. 8, No. 11, e70052, 01.11.2024.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
TY - JOUR
T1 - Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma
T2 - Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
AU - Mai, Elias K.
AU - Nogai, Axel
AU - Lokhorst, Henk M.
AU - van der Holt, Bronno
AU - Zweegman, Sonja
AU - Weisel, Katja C.
AU - Croockewit, Sandra
AU - Jauch, Anna
AU - Hillengass, Jens
AU - Stevens-Kroef, Marian
AU - Raab, Marc S.
AU - Broijl, Annemiek
AU - Bos, Gerard M.J.
AU - Brossart, Peter
AU - Ypma, Paula
AU - Hanoun, Christine
AU - Bertsch, Uta
AU - Hielscher, Thomas
AU - Salwender, Hans J.
AU - Scheid, Christoph
AU - Goldschmidt, Hartmut
AU - Sonneveld, Pieter
N1 - Funding Information: The HOVON-65/GMMG-HD4\u00A0trial was supported by the Dutch Cancer Foundation, the German Federal Ministry of Education and Research, and unrestricted Grant No. MMY3003 from Janssen-Cilag-Ortho Biotech. The German-speaking Myeloma Multicenter Group was supported by grants from Novartis, Amgen (No. P2004-0060), Chugai, and Roche. The investigators thank all participating patients and their families. Further, the authors thank the HOVON trial team, the \u201CZentrum zur Koordination klinischer Studien (KKS)\u201D (Heidelberg, Germany), and all participating study sites. Supported by the Dutch Cancer Foundation, the German Federal Ministry of Education and Research, and unrestricted Grant No. MMY3003 from Janssen-Cilag-Ortho Biotech. The GMMG was supported by grants from Novartis, Amgen (No. P2004-0060), Chugai, and Roche. Editorial support was provided by Mareike Hampel contracted by the GMMG (Heidelberg University Hospital, Heidelberg, Germany). Open Access funding enabled and organized by Projekt DEAL. Funding Information: The HOVON\u201065/GMMG\u2010HD4 trial was supported by the Dutch Cancer Foundation, the German Federal Ministry of Education and Research, and unrestricted Grant No. MMY3003 from Janssen\u2010Cilag\u2010Ortho Biotech. The German\u2010speaking Myeloma Multicenter Group was supported by grants from Novartis, Amgen (No. P2004\u20100060), Chugai, and Roche.
PY - 2024/11/1
Y1 - 2024/11/1
U2 - 10.1002/hem3.70052
DO - 10.1002/hem3.70052
M3 - Comment/Letter to the editor
SN - 2572-9241
VL - 8
JO - HemaSphere
JF - HemaSphere
IS - 11
M1 - e70052
ER -